1 Multi-site clinical validation of Isothermal Amplification based SARS-COV-2 detection assays

2 using different sampling strategies

- 3
- 4 Kanan T. Desai¹, Karla Alfaro², Laura Mendoza³, Matthew Faron⁴, Brian Mesich⁴, Mauricio
- 5 Maza², Rhina Dominguez⁵, Adriana Valenzuela³, Chyntia Díaz Acosta³, Magaly Martínez³, Juan C.
- 6 Felix⁴, Rachel Masch^{2,6}, Sofia Gabrilovich⁷, Michael Plump⁷, Akiva P. Novetsky^{7,8}, Mark H.
- 7 Einstein^{7,8}, Nataki C. Douglas⁷, Miriam Cremer^{2,9}, Nicolas Wentzensen¹
- 8

9 Affiliations

- ¹Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Rockville, USA
- ²Basic Health International, Pittsburgh, USA
- ¹³ ³Instituto de Investigaciones en Ciencias de la Salud, Universidad Nacional de Asunción, San
- 14 Lorenzo, Paraguay
- ⁴Medical College of Wisconsin, Milwaukee, USA
- ⁵Research Unit, El Salvador National Institute of Health (INS), El Salvador
- 17 ⁶The Mount Sinai Hospital, New York, USA
- 18 ⁷Rutgers New Jersey Medical School, Newark, USA
- ¹⁹ ⁸Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA
- ⁹Cleveland Clinic Lerner College of Medicine, Clevland, USA
- 21
- 22 Corresponding author

- 24 Kanan T. Desai
- 25 Clinical Genetics Branch
- 26 Division of Cancer Epidemiology and Genetics
- 27 National Cancer Institute, NIH, USA
- 28 Email: kanan.desai@nih.gov
- 29

²³

31 Abstract (Limit: 250; Current: 250)

32

33 Background:

34 Isothermal amplification-based tests were developed as rapid, low-cost, and simple alternatives

35 to real-time reverse transcriptase-polymerase chain reaction (RT-PCR) tests for SARS-COV-2

36 detection.

37 Methods:

38 Clinical performance of two isothermal amplification-based tests (Atila Biosystems iAMP

39 COVID-19 detection test and OptiGene COVID-19 Direct Plus RT-LAMP test) was compared to

40 clinical RT-PCR assays using different sampling strategies. A total of 1378 participants were

41 tested across four study sites.

42 <u>Results:</u>

43 Compared to standard of care RT-PCR testing, the overall sensitivity and specificity of the Atila iAMP test for detection of SARS-CoV-2 were 76.2% and 94.9%, respectively, and increased to 44 88.8% and 89.5%, respectively, after exclusion of an outlier study site. Sensitivity varied based 45 on the anatomic collected site. Sensitivity for nasopharyngeal was 65.4% (range across study 46 sites:52.8%-79.8%), mid-turbinate 88.2%, saliva 55.1% (range across study sites:42.9%-77.8%) 47 48 and anterior nares 66.7% (range across study sites:63.6%-76.5%). The specificity for these 49 anatomic collection sites ranged from 96.7% to 100%. Sensitivity improved in symptomatic patients (overall 82.7%) and those with a higher viral load (overall 92.4% for ct≤25). Sensitivity 50 51 and specificity of the OptiGene Direct Plus RT-LAMP test, conducted at a single study-site, were 52 25.5% and 100%, respectively.

53 Conclusions

- 54 The Atila iAMP COVID test with mid-turbinate sampling is a rapid, low-cost assay for detecting
- 55 SARS-COV-2, especially in symptomatic patients and those with a high viral load, and could be
- 56 used to reduce the risk of SARS-COV-2 transmission in clinical settings. Variation of
- 57 performance between study sites highlights the need for site-specific clinical validation of these
- 58 assays before clinical adoption.
- 59
- 60 Keywords
- 61
- 62 COVID-19, SARS-COV-2, Isothermal Amplification, clinical validation, cancer screening
- 63
- 64

Main text (Limit:3000 excluding material-methods; Current: Total: 504+1988=2492 exclusive 65 66 of material-methods) 67 Introduction 68 69 The COVID-19 (Coronavirus Disease of 2019) pandemic has led to major disruptions in health services worldwide. In many developed nations, widespread SARS-CoV-2 (Severe acute 70 respiratory syndrome coronavirus 2) testing and mass vaccination has allowed for a return to 71 72 most elective health services. However, many low- and middle- income countries (LMICs) have 73 limited access to testing and vaccination and continue to struggle to contain COVID-19 (1) (2). 74 As the COVID-19 crisis continues, considerable reductions of cancer screening, cancer control, 75 and elective clinical services remain (3). The safe return to cancer screening and elective testing and procedures during the pandemic, especially in low vaccination regions, requires 76 77 reliable SARS-CoV-2 testing for both providers and patients. 78 79 Numerous SARS-CoV-2 detection assays have been developed and introduced into the market under emergency use authorizations (EUA) (4). EUAs are granted primarily based on analytic 80 sensitivity (i.e., Limit of Detection (LOD)) and analytic specificity (i.e., cross-reactivity) with 81 82 limited clinical validations. Yet, a thorough clinical performance evaluation of SARS-CoV-2 83 assays in important to understand the strengths, limitations, and specific applications of these assays (5). Current Centers for Disease Control (CDC) guidelines recommend the use of 84 laboratory-based nucleic acid amplification test (NAAT) (e.g., reverse trasnscriptase-85 polymerase chain reaction (RT-PCR)) for confirmatory testing. Specimens that are considered 86

87	optimal for detection include nasopharyngeal (NP), nasal mid-turbinate, and anterior nasal
88	swabs. Currently, the CDC does not recommend NAAT that use oral specimens (e.g., saliva) for
89	confirmatory testing (6–8).
90	
91	In addition to clinical performance, several other factors are important to consider when
92	assessing feasibility of an assay for use in different environments and clinical settings. These
93	factors include time to run the assay, hands-on time, throughput, ease of implementation, and
94	cost. Furthermore, the possibility to use different sampling approaches, including self-
95	collection, can be an important distinguishing feature since many LMICs have limited personal
96	protective equipment (PPE). While RT-PCR assays fulfill the desired clinical performance criteria,
97	they are not ideal for primary care clinics in resource-limited settings as point-of-care SARS-
98	COV-2 screening tests due to high costs as well as longer turn around times and need for
99	technical expertise (9). While rapid antigen-based tests address these limitations, they lack
100	sensitivity to rule out an active infection (10). Isothermal amplification-based reverse
101	transcription assays may fill this gap as they are more rapid (take \sim 1 hour), cheaper (\sim 5-15
102	USD per test) and simpler (not needing RNA extraction) than RT-PCR based tests (11), but
103	require clinical validation.
104	

The primary objective of this study was to evaluate the clinical performance and operational
characteristics of two isothermal amplification-based SARS-CoV-2 tests: 1) iAMP COVID-19
detection test (Atila BioSystems, USA) targeting N and ORF1a-genes of SARS-COV-2 virus, and 2)
COVID-19 Direct Plus RT-LAMP test (OptiGene Ltd., UK) targeting ORF1ab-gene of SARS-COV-2

109	virus, compared to clinical RT-PCR tests. The secondary objective was to evaluate the influence
110	of different sampling strategies on the detection of SARS-COV-2. One specific use for such
111	assays is rapid SARS-COV-2 testing to allow for a safer return to preventive clinical encounters
112	such as cancer screening in low- and middle-income countries.
113	
114	Materials and Methods
115	
116	Study design and population
117	
118	A cross-sectional study was conducted from December 2020 to April 2021 at four clinical sites:
119	Hospital Nacional de Santa Ana, El Salvador; Hospital Materno Infantil de San Lorenzo,
120	Ministerio de Salud Pública (MSP-BS), Paraguay; Medical College of Wisconsin (MCW), USA; and
121	Rutgers New Jersey Medical School (NJMS), USA (Table 1). The study protocol and sampling
122	strategies varied slightly across the study sites, based on local requirements.
123	
124	At the El Salvador site, 900 asymptomatic and symptomatic subjects presenting for SARS-COV-2
125	testing were enrolled. A standard NP swab for RT-PCR was collected from all the participants for
126	clinical diagnosis. A second provider-collected dry NP swab and a self-collected direct saliva
127	sample were obtained from study participants in parallel for the Atila iAMP test.
128	
129	At the Paraguay site, 265 asymptomatic and symptomatic subjects presenting for SARS-COV-2
130	testing were enrolled in the study. A standard NP swab for RT-PCR was collected from all the

131 participants for clinical diagnosis. In addition, for those consenting to participate in the study, a

- 132 leftover of the clinical NP swab placed in viral transport medium (VTM) and a second parallel
- 133 self-collected direct saliva sample were obtained for the Atila iAMP test.
- 134

135 At the Wisconsin (MCW) site, 128 symptomatic and asymptomatic subjects presenting for

136 SARS-COV-2 testing were enrolled in the study. A standard NP swab for RT-PCR was collected

137 from all the participants for clinical diagnosis. In addition, for those consenting to participate, a

138 second provider-collected dry NP swab, a self-collected dry mid-turbinate swab, a self-collected

dry anterior nares swab, and a self-collected direct saliva sample were obtained in parallel for

140 Atila iAMP test.

141

At the New Jersey (NJMS) site, 55 symptomatic SARS-COV-2 positive patients, based on a prior 142 143 RT-PCR assay, who were admitted for observation and management of COVID-19 were enrolled 144 in the study. 28 of 55 (50.9%) of the patients were enrolled within 24 hours, 14 of 55 (25.5%) within 48 hours, and 6 of 55 (10.9%) within 72 hours of the sample collection for the RT-PCR 145 test. In addition, 30 participants expected to be negative for the SARS-COV-2 infection (i.e., no 146 SARS-COV-2 symptoms) were enrolled. A negative SARS-COV-2 RT-PCR test obtained within five 147 148 days of test sample collection was performed on 28 (93.3%) of these 30 participants. Regardless 149 of the RT-PCR status, for everyone enrolled in the study, a provider-collected dry NP swab and a provider-collected dry anterior nares swab was obtained at the time of enrollment for the Atila 150 iAMP test. In addition, a provider-collected oropharyngeal (OP) swab placed in Sigma Virocult[®] 151

- 152 medium (MSW, UK) and a self-collected direct saliva sample was also obtained at the time of
- 153 enrollment for the OptiGene Direct Plus RT-LAMP test.

154

- 155 The study protocol at all the sites was approved by the respective local institutional ethical
- 156 review boards.
- 157
- 158 <u>Test and RT-PCR assays</u>
- 159

160 All the assays were performed as per the manufacturer's instruction for use (IFU).

161

The Atila iAMP test was performed on the same day of test sample collection for all samples in 162 El Salvador, and 81 of 85 (95.3%) samples in New Jersey (NJMS). The samples not tested on the 163 164 same day were frozen at -20°C in Paraguay and -80°C in Wisconsin (MCW) and tested in batches. A validated RT-PCR system (i.e., Biorad CFX96 RT system or Atila PowerGene 9600 Plus 165 RT-PCR system) with FAM/HEX fluorescence detection was used for reaction run and detection. 166 Positive and negative controls were run for each batch, and the batch was considered valid only 167 if both controls were valid. The individual sample test result was determined to be positive if an 168 169 exponential amplification curve with cycle threshold (ct)<50 was present in the FAM (ORF-1a/b 170 or N-genes) channel. The test result was determined to be negative if the FAM channel did not have an amplication curve, and the HEX (internal control) channel had an exponential 171 amplification curve with ct<50. The test was determined invalid if no amplification was 172 detected in both FAM and HEX channels, in which case the test was repeated. If the repeat run 173

was also invalid, then the that sample was considered invalid. In total, 1.0% of NP, 1.4% of 174 175 anterior nares, 3.9% of mid-turbinate, and 0% of saliva samples had invalid results. Less than 1% (0.6%) of saliva samples could not be tested secondary to the samples being predominantly 176 177 phlegm. 178 With few exceptions [5 of 85 (6.0%)], the OptiGene Direct Plus RT-LAMP test was performed on 179 the same day of the test sample collection. A Genie® III or II platform (OptiGene, UK) was used 180 181 for the reaction run and detection. Positive and negative controls were run for each batch of 182 samples, and the batch was considered valid only if both controls were valid. The Genie® software automatically analyzed the individual sample test results as positive or negative based 183 184 on the amplification plot and annealing temperature. The test result is reported positive if the fluorescence level of the amplification curve rises above a defined threshold and the peak of 185 186 the annealing curve is above a defined threshold and lies within a specified temperature range. All of the OP and anterior nares samples were tested. 19% of the saliva samples were not 187 tested because those samples were predominantly phlegm without saliva. 188 189 A single run was performed for each sample at all study sites except at NJMS which performed 190 191 duplicate runs for each sample. To ensure comparability across the sites, for the pooled 192 analysis, the first of the duplicate run at NJMS was used. 193

194 <u>Statistical analysis</u>

196	Pooled and study site-specific analyses were performed overall and stratified by different
197	sampling strategies. For the overall analysis, if any sample anatomic collection site tested
198	positive, that subject was identified as positive for that test assay. If all collection site samples
199	were negative for the subject, the subject was considered negative for that test assay.
200	
201	The NP sample for the RT-PCR test used for clinical diagnosis was considered the reference
202	method. The sensitivity was defined as the proportion of RT-PCR positive samples which tested
203	positive by the test assay, and specificity was defined as the proportion of the RT-PCR negative
204	samples which tested negative by the test assay. Additional stratified analyses by the ct-value
205	for the RT-PCR, as a surrogate marker for the viral load, and history of symptoms were also
206	performed wherever the data was available. History of symptoms was collected from the
207	subjects at the time of sample collection. 95% confidence intervals (CI) were calculated for the
208	sensitivity and specificity measures. Imbalances in paired sample results were evaluated using
209	Mc-Nemar's test, with a p-value < 0.05 considered statistically significant. Data analysis was
210	performed using IBM [®] SPSS software.
211	
212	Results
213	
214	Atila iAMP test
215	
216	In the overall analysis (Figure 1), the sensitivity of the Atila iAMP test was 76.2% (95% CI: 71.1-
217	80.7) and the specificity was 94.9% (95% CI: 93.3-96.1) for detection of SARS-CoV-2. Stratified

218	by study site, the sensitivity was 63.8% (95% CI: 55.9-71.2) in El Salvador, 88.5% (95% CI: 79.9-
219	94.3) in Paraguay, 88.9% (95% CI: 65.3-98.6) in Wisconsin, and 89.1% (95% CI:77.8-95.9) in New
220	Jersey. The specificity was 97.2% (95% CI: 95.7-98.2), 81.3% (95% CI: 74.7-86.7), 100% (95% CI:
221	96.6-100) and 100% (95% CI: 88.4-100), respectively. Since the El Salvador site's sensitivity was
222	significantly lower than all the other sites, and considered an outlier, we conducted an overall
223	pooled analysis excluding El Salvador, which demonstrated an overall sensitivity of 88.8% (95%
224	CI: 82.8-93.2) and an overall specificity of 89.5% (95% CI: 85.6-92.7).
225	
226	We evaluated the clinical performance of individual sampling strategies (Figure 2). The
227	sensitivity and specificity of the provider-collected NP sample was 65.4% (95% CI: 59.9-70.6)
228	and 97.6% (95% CI: 96.5-98.4). Since sensitivity at the El Salvador site was significantly different
229	than all the other sites, we recalculated the overall sensitivity excluding El Salvador, which led
230	to the sensitivity of 78.9% (95% CI: 71.6-85.1) and specificity of 95.4% (95% CI: 92.4-97.5).
231	
232	Comparing the other sampling strategies to the reference standard NP sample, self-collected
233	dry mid-turbinate sample (only collected at MCW) was found to be most sensitive [88.2% (95%
234	CI: 63.6-98.5)] and specific [100% (95% CI: 96.5-100)]. Self-collected saliva samples, excluding El
235	Salvador (due to significantly different estimate than other sites), had an overall sensitivity of
236	74.5% (95% CI: 64.9-82.6) and overall specificity of 91.8% (95% CI: 87.9-94.7). The self-collected
237	dry anterior nares sample was the least sensitive strategy with the overall sensitivity of 66.7%
238	(95% CI: 54.6-77.3) and overall specificity of 100% (95% CI: 97.3-100). Since anterior nares
239	sample was not collected at the El Salvador study site and none of the study sites had

significantly different estimate than other sites for anterior nares sample, no exclusion wasmade.

243	Assuming that viral load would influence accuracy, we analyzed the sensitivity at different ct-
244	values on RT-PCR among the positive subjects (Figure 3). Restricting the analysis to samples
245	with ct \leq 35, ct \leq 30, ct \leq 25, and ct \leq 20 increased the sensitivity to 82.6%, 97%, 100% and 100% for
246	NP samples and 68%, 86.1%, 88.9%, and 100% for anterior nares samples in New Jersey (NJMS)
247	and 79.8%, 81.3%, 88.4%, and 100% for NP samples and 73.8%, 73.8%, 79.7%, and 84.3% for
248	saliva samples in Paraguay. The respective corresponding percentages for El Salvador were
249	65.9%, 78.1%, 83.6%, and 89.1% for NP samples and 52.8%, 58.3%, 64.4% and 65.5% for saliva
250	samples. Although the sensitivity increased in El Salvador with an increase in viral load (i.e, at
251	lower ct-values), within each ct-value strata, the sensitivity in El Salvador was still lower than in
252	Paraguay and New Jersey for each anatomic collection sites.
253	
254	The mean ct-value on RT-PCR in El Salvador among the RT-PCR positive asymptomatic subjects
255	was 30.0 (95% CI: 25.6-30.4), and among symptomatic subjects was 22.5 (95% CI: 20.2-24.8).
256	The respective corresponding values in Paraguay were 18 (95% CI: 13.7-22.4) and 17.5 (95% CI:
257	15.8-19.2). The mean ct-value on RT-PCR in New Jersey among the RT-PCR positive subjects was
258	25.7 (95% CI: 23.9-27.5); all RT-PCR positive subjects were hospitalized for observation and
259	management of COVID-19 and so likely symptomatic. The sensitivity of the NP sample in El
260	Salvador among symptomatic subjects was significantly higher [65.1% (95% CI: 54.1-75.1)] than
261	among asymptomatic subjects [39.0% (95% CI: 28.0-50.8)] (Figure 4). The difference was not

262	significant between symptomatic and asymptomatic subjects for NP samples in Paraguay, saliva
263	in El Salvador, and saliva in Paraguay. Among the symptomatics subjects, the sensitivity was
264	significantly higher for saliva samples in Parguay [74.3% (95% CI: 62.4-84.0)] than in El Salvador
265	[51.2% (95% CI: 40.1-62.1)]; the difference was not significant for the NP samples in Paraguay
266	[81.7% (95% CI: 70.7-89.9)] and New Jersey [78% (95% CI: 64-88.5)] and in El Salvador [65.1%
267	(95% CI: 54.1-75.1)]. Among the asymptomatic subjects, the difference for either NP [69.2%
268	(95% CI: 38.6-90.9) in Paraguay and 39% (95% CI: 28.0-50.8) in El Salvador] or saliva samples
269	[71.4% (95% CI: 41.9-91.6) in Paraguay and 33.8% (95% CI: 23.4-45.4) in El Salvador] was not
270	significantly different between Parguay and El Salvador.
271	
272	OptiGene Direct Plus RT-LAMP test
273	
274	The overall sensitivity and specificity of the OptiGene Direct Plus RT-LAMP test were 25.5%
275	(95% CI: 14.7-39) and 100% (95% CI: 88.4-100), respectively (Figure 5). The estimates did not
276	differ significantly by different sampling strategies or duplicate testing. Furthermore, when
277	limiting the analysis to test samples collected within 24 hrs of RT-PCR sample collection, the
278	overall sensitivity was still only 33.3%.
279	
280	Discussion
281	
282	The current study evaluated the clinical performance of two isothermal amplification tests for
283	detection of SARS-CoV-2. The overall sensitivity and specificity of the Atila iAMP test for

284	detection of SARS-CoV-2, excluding the outlier study site, were 88.8% and 89.5%, respectively.
285	The sensitivity, excluding the outlier study site, was 78.9% for nasopharyngeal, 88.2% for self-
286	sampled mid-turbinate, 74.5% for direct saliva and 66.7% for anterior nares samples. The
287	specificity for these sites ranged from 91.8% to 100%. The sensitivity increased with higher viral
288	load (i.e., at lower ct-values) and among symptomatic as compared to asymptomatic
289	participants. The sensitivity and specificity of the OptiGene Direct Plus RT-LAMP test, conducted
290	at a single site, were 25.5% and 100%, respectively.

291

There is scant literature on the performance of the Atila iAMP COVID test. We identified only 292 293 one clinical performance evaluation of the Atila iAMP COVID test on the direct, non-extracted samples, which is the recommended application as per EUA by the manufacturer. This small-294 295 scale evaluation (n=197) showed a sensitivity of 44.1% and specificity of 96.6% for the Atila 296 iAMP test on NP swabs with a large number (35.5% or 70/197) of invalid results (12). A small (n=50) analytic and clinical validation study on the Atila iAMP assay showed the analytic LOD 297 for the assay to be 50-100 copies/reaction for ORF1-a/b gene and 1-10 for the N gene, which is 298 299 higher than that of RT-PCR (average range of 1-10) (13). This may explain our finding of lower clinical sensitivity of the assay at higher ct-values, considering ct-values as a surrogate marker 300 301 for the viral load, which may not always be precise (14). In the clinical validation by the same 302 group, the assay was found to have 100% agreement with the RT-PCR. However, this validation was on extracted RNA and was based on 46/50 samples that have ct≤30. Another small (n=50) 303 clinical validation (15), again on extracted RNA, showed the sensitivity and specificity of the 304 305 assay to be 82.8% and 100%, respectively, with all five false-negative samples to have $ct \ge 35$.

306

307	The OptiGene Direct Plus RT-LAMP COVID assay has been previously clinically validated by the
308	NHS trust to have a sensitivity of 70% for swabs and 79% for saliva, with an increase in
309	sensitivity to 100% for swabs at ct≤25 (16). However, similar to our validation, such high
310	sensitivity was not confirmed by other groups, which showed the sensitivity in the range of
311	46.7% (17)and 34%, including false-negative results on symptomatic high viral load subjects
312	(18). Our validation study was based on kits purchased from the manufacturer, using fresh
313	samples (not freeze-thawed samples) collected and placed in the VTM recommended by the
314	manufacturer, and run as per the instructions provided by the manufacturer. Furthermore,
315	even though the reference RT-PCR used in our assay targeted E or N2 and S gene in addition to
316	the ORF1-a/b gene, given that a NP swab based RT-PCR is the accepted reference standard for
317	the SARS-COV-2 diagnosis (7,8), we believe that clinical sensitivity of the assay should not be
318	affected by the differences in gene targets between the assays. While it has been suggested
319	that assays targeting the N gene are not a valid reference standard to evaluate the OptiGene
320	Direct Plus RT-LAMP assay (19), this is not supported by clinical studies.

321

It is important to note that the IFU's for both assays state the need to confirm the negative test result with a more sensitive RT-PCR test, and do not claim to be the final screening answer (20). However, as compared to the RT-PCR assays, which may sometimes take >24 hr of turnaround time (TOT) with considerable cost, the isothermal amplification-based assay's advantage is its rapid TOT (~1 hour), lower cost, and ease of performance (no nuleic acid extraction needed). Thus, it can cheaply and rapidly identify high viral load subjects who are likely to be most

328	infectious (21)(22). Moreover, there is at least some evidence to suggest that RT-PCR positivity
329	does not necessarily translate into infectivity because it can detect the shedding of post-
330	infectious viral RNA particles shedding, particularly among post-symptomatic patients (23,24).
331	The Atila iAMP has similar advantages as the rapid antigen tests with regard to ease of
332	operability and quick TOT, but provides higher sensitivity (reported to be 67-73% for rapid
333	antigen test (25,26)) resulting in more reassurance of a negative test result.
334	
335	Variation in the performance of both the assays across various study sites in our evaluation and
336	notable differences to other studies cannot be ignored. It demonstrates the limitations of EUAs
337	which may not necessarily translate to acceptable clinical performance for all tests in all
338	settings. A thorough clinical validation of diagnostic assays on a standardized panel of samples
339	in clinical settings is advisable before its widespread adoption for clinical use.
340	
341	We do not fully understand the reason for the variation in test performance across study-sites.
342	Importantly, the populations at each site was different with respect to SARS-CoV-2 prevalence,
343	clinical symptoms, and other factors, but stratified analyses showed similar performance at all
344	sites except for El Salvador. Given that invalid results were rare and did not differ across the
345	study sites and there was no consistent pattern observed in ct-values for the internal control
346	[mean ct-values for the internal control for NP: 28.4 (95% CI: 28.1-28.7) (El Salvador), 34.1 (95%
347	CI: 32.8-35.1) (MCW), 22.7 (21.9-23.4) (Paraguay), 25.4 (23.4-27.3) (NJMS); for saliva: 19.4 (95%
348	CI: 19.1-19.7), 23.6 (95% CI: 23.1-24.2) (MCW), 22.1 (21.3-22.8) (Paraguay)], we do not attribute
349	the lower sensitivity in our validation in El Salvador to sampling variation. Rather we

350	hypothesize the lower sensitivity of the Atila iAMP test in El Salvador to be related to multiple
351	factors: relatively higher proportion of asymptomatic subjects as compared to Paraguay (69.8%
352	versus 21.9%) and operator-dependent nature of the assay due to the hands-on nature of the
353	test to set up the reaction (27). However, given that on stratified analysis by symptoms and ct-
354	values, the sensitivity was still lower in El Salvador than other sites within the strata, makes the
355	second explanation more likely. Variation in the reference standard RT-PCR method and RNA
356	extraction kits used across the study sites as well as variation in duration of performing the test
357	assay after collection is a limitation of our study and may also have influence on the study site-
358	wide variations.
359	
360	Conclusions
361	
362	In this first large-scale multi-site clinical evaluation of the Atila BioSystems iAMP COVID-19
363	
	detection test, the assay showed good sensitivity with high specificity for detection of SARS-
364	detection test, the assay showed good sensitivity with high specificity for detection of SARS- CoV-2, particularly on high viral load (i.e., ct≤25) NP samples. In addition, it also showed
364 365	detection test, the assay showed good sensitivity with high specificity for detection of SARS- CoV-2, particularly on high viral load (i.e., ct≤25) NP samples. In addition, it also showed moderate sensitivity for ct≤35 NP samples and ct≤25 saliva samples. Overall, the sensitivity was
364 365 366	detection test, the assay showed good sensitivity with high specificity for detection of SARS- CoV-2, particularly on high viral load (i.e., ct≤25) NP samples. In addition, it also showed moderate sensitivity for ct≤35 NP samples and ct≤25 saliva samples. Overall, the sensitivity was superior for NP and mid-turbinate samples compared to saliva and anterior nares samples. The
364 365 366 367	detection test, the assay showed good sensitivity with high specificity for detection of SARS- CoV-2, particularly on high viral load (i.e., ct≤25) NP samples. In addition, it also showed moderate sensitivity for ct≤35 NP samples and ct≤25 saliva samples. Overall, the sensitivity was superior for NP and mid-turbinate samples compared to saliva and anterior nares samples. The rapid TOT, low cost, and lack of need for nucleic acid extraction make Atila iAMP test a
364 365 366 367 368	detection test, the assay showed good sensitivity with high specificity for detection of SARS- CoV-2, particularly on high viral load (i.e., ct≤25) NP samples. In addition, it also showed moderate sensitivity for ct≤35 NP samples and ct≤25 saliva samples. Overall, the sensitivity was superior for NP and mid-turbinate samples compared to saliva and anterior nares samples. The rapid TOT, low cost, and lack of need for nucleic acid extraction make Atila iAMP test a reasonable alternative screening test for SARS-COV-2 for patients and providers in outpatient
364 365 366 367 368 369	detection test, the assay showed good sensitivity with high specificity for detection of SARS- CoV-2, particularly on high viral load (i.e., ct≤25) NP samples. In addition, it also showed moderate sensitivity for ct≤35 NP samples and ct≤25 saliva samples. Overall, the sensitivity was superior for NP and mid-turbinate samples compared to saliva and anterior nares samples. The rapid TOT, low cost, and lack of need for nucleic acid extraction make Atila iAMP test a reasonable alternative screening test for SARS-COV-2 for patients and providers in outpatient clinics to identify likely infectious subjects. When implemented with other COVID safety
364 365 366 367 368 369 370	detection test, the assay showed good sensitivity with high specificity for detection of SARS- CoV-2, particularly on high viral load (i.e., ct≤25) NP samples. In addition, it also showed moderate sensitivity for ct≤35 NP samples and ct≤25 saliva samples. Overall, the sensitivity was superior for NP and mid-turbinate samples compared to saliva and anterior nares samples. The rapid TOT, low cost, and lack of need for nucleic acid extraction make Atila iAMP test a reasonable alternative screening test for SARS-COV-2 for patients and providers in outpatient clinics to identify likely infectious subjects. When implemented with other COVID safety measures, such low cost testing can provide an approach for the safe reopening and daily

- of care. However, inconsistency observed in assay performance across the study sites highlights
- the need for a rigorous site-specific clinical performance evaluation of the isothermal-
- amplification-based assays before their clinical adoption.
- 375

376 References

- 1. WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard
- 378 With Vaccination Data [Internet]. [cited 2021 May 11]. Available from:
- 379 https://covid19.who.int/
- 2. COVID-19 Vaccine Market Dashboard | UNICEF Supply Division [Internet]. [cited 2021]
- 381 May 11]. Available from: https://www.unicef.org/supply/covid-19-vaccine-market-
- 382 dashboard
- 383 3. Cancino RS, Su Z, Mesa R, Tomlinson GE, Wang J. The impact of COVID-19 on cancer
- 384 screening: challenges and opportunities [Internet]. Vol. 6, JMIR Cancer. JMIR Publications
- 385 Inc.; 2020 [cited 2021 May 11]. Available from:
- 386 https://pubmed.ncbi.nlm.nih.gov/33027039/
- 4. In Vitro Diagnostics EUAs Molecular Diagnostic Tests for SARS-CoV-2 | FDA [Internet].
- 388 [cited 2021 May 11]. Available from: https://www.fda.gov/medical-devices/coronavirus-
- 389 disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-
- 390 diagnostics-euas-molecular-diagnostic-tests-sars-cov-2#individual-molecular
- 391 5. Mitchell SL, St George K, Rhoads DD, Butler-Wu SM, Dharmarha V, McNult P, et al.
- 392 Understanding, verifying, and implementing emergency use authorization molecular
- diagnostics for the detection of sars-cov-2 RNA [Internet]. Vol. 58, Journal of Clinical

394	Microbiology. American Society for Microbiology; 2020 [cited 2021 May 11]. Available
395	from: http://jcm.asm.org/

- 396 6. Nucleic Acid Amplification Tests (NAATs) | CDC [Internet]. [cited 2021 May 28]. Available
- 397 from: https://www.cdc.gov/coronavirus/2019-ncov/lab/naats.html
- 398 7. A Composite Reference Standard for COVID-19 Diagnostic Accuracy Studies: a roadmap -
- The Centre for Evidence-Based Medicine [Internet]. [cited 2021 May 14]. Available from:
- 400 https://www.cebm.net/covid-19/a-composite-reference-standard-for-covid-19-
- 401 diagnostic-accuracy-studies-a-roadmap/
- 402 8. Laboratory testing of 2019 novel coronavirus (2019-nCoV) in suspected human cases:
- 403 interim guidance, 17 January 2020 [Internet]. [cited 2021 May 14]. Available from:
- 404 https://www.who.int/publications/i/item/laboratory-testing-of-2019-novel-coronavirus-
- 405 (-2019-ncov)-in-suspected-human-cases-interim-guidance-17-january-2020
- 406 9. Favresse J, Gillot C, Oliveira M, Cadrobbi J, Elsen M, Eucher C, et al. Head-to-Head
- 407 Comparison of Rapid and Automated Antigen Detection Tests for the Diagnosis of SARS-
- 408 CoV-2 Infection. J Clin Med [Internet]. 2021 Jan 13 [cited 2021 May 11];10(2):265.
- 409 Available from: /pmc/articles/PMC7828347/
- 410 10. Interim Guidance for Antigen Testing for SARS-CoV-2 | CDC [Internet]. [cited 2021 May
- 411 28]. Available from: https://www.cdc.gov/coronavirus/2019-
- 412 ncov/lab/resources/antigen-tests-guidelines.html#table1
- 413 11. COVID-19 AtilaBiosystems [Internet]. [cited 2021 May 11]. Available from:
- 414 https://atilabiosystems.com/our-products/covid-19/
- 415 12. Ganesan S. Evaluation of seven different rapid methods for nucleic acid detection of

	416	SARS-COV-2 virus 2 Running title: Rapid methods for nucleic acid detection of SARS-CO)V-
--	-----	---	-----

- 417 2 virus [Internet]. Preprint on medRxiv. [cited 2021 May 14]. Available from:
- 418 https://doi.org/10.1101/2021.04.15.21255533
- 419 13. SARS-CoV-2 molecular assay evaluation: results FIND [Internet]. [cited 2021 May 14].
- 420 Available from: https://www.finddx.org/covid-19/sarscov2-eval-molecular/molecular-
- 421 eval-results/
- 14. Ct Values: What They Are and How They Can be Used Version 2 Is there variability in
- 423 Ct values? 2021;
- 424 15. Bulterys PL, Garamani N, Stevens B, Sahoo MK, Huang CH, Hogan CA, et al. Comparison
- 425 of a laboratory-developed test targeting the envelope gene with three nucleic acid
- 426 amplification tests for detection of SARS-CoV-2. J Clin Virol [Internet]. 2020 Aug 1 [cited
- 427 2021 May 14];129. Available from: https://pubmed.ncbi.nlm.nih.gov/32535398/
- 428 16. Rapid evaluation of OptiGene RT-LAMP assay (direct and RNA formats) GOV.UK
- 429 [Internet]. [cited 2021 May 14]. Available from:
- 430 https://www.gov.uk/government/publications/rapid-evaluation-of-optigene-rt-lamp-
- 431 assay-direct-and-rna-formats/rapid-evaluation-of-optigene-rt-lamp-assay-direct-and-rna-
- 432 formats
- 433 17. Iacobucci G. Covid-19: Rapid test missed over 50% of positive cases in Manchester pilot.
- 434 BMJ. 2020 Nov 6;371:m4323.
- 435 18. Wilson-Davies ESW, Mahanama AIK, Samaraweera B, Ahmed N, Friar S, Pelosi E.
- 436 Concerns regarding the sensitivity of the OptiGene direct SARS-CoV-2 LAMP assay and its
- 437 suitability for use in at-risk groups and hospital staff [Internet]. Vol. 82, Journal of

438	Infection. W.B.	. Saunders Ltd;	2021	cited 2021 May	y 14].	p. 282-327.	Available from:
-----	-----------------	-----------------	------	----------------	--------	-------------	-----------------

- 439 /pmc/articles/PMC7870105/
- 440 19. Fowler DV, Douglas DA, Godfrey PK, Williams PA, Beggs PA, Kidd S, et al. Critical
- 441 evaluation of the methodology used by Wilson-Davies et al., (2020) entitled "Concerning
- the Optigene Direct LAMP assay, and it's use in at-risk groups and hospital staff." Vol. 82,
- Journal of Infection. W.B. Saunders Ltd; 2021. p. 282–327.
- 444 20. Direct RT-LAMP for Hospital Screening | The BMJ [Internet]. [cited 2021 May 14].
- 445 Available from: https://www.bmj.com/content/371/bmj.m4323/rr-1
- 446 21. Sohni Y. Variation in LOD Across SARS-CoV-2 Assay Systems: Need for Standardization.
- 447 Lab Med. 2021 Mar 15;52(2):107–15.
- 448 22. Jefferson T, Spencer EA, Brassey J, Heneghan C. Viral cultures for COVID-19 infectious
- 449 potential assessment a systematic review. Clin Infect Dis [Internet]. 2020 Dec 3 [cited
- 450 2021 May 14]; Available from: https://pubmed.ncbi.nlm.nih.gov/33270107/
- 451 23. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. Virological
- 452 assessment of hospitalized patients with COVID-2019. Nature [Internet]. 2020 May 28
- 453 [cited 2021 May 14];581(7809):465–9. Available from:
- 454 https://pubmed.ncbi.nlm.nih.gov/32235945/
- 455 24. Cevik M, Kuppalli K, Kindrachuk J, Peiris M. Virology, transmission, and pathogenesis of
- 456 SARS-CoV-2. BMJ [Internet]. 2020 Oct 23 [cited 2021 May 14];371. Available from:
- 457 http://dx.doi.org/10.1136/bmj.m3862
- 458 25. Favresse J, Gillot C, Oliveira M, Cadrobbi J, Elsen M, Eucher C, et al. Head-to-Head
- 459 Comparison of Rapid and Automated Antigen Detection Tests for the Diagnosis of SARS-

- 460 CoV-2 Infection. J Clin Med [Internet]. 2021 Jan 13 [cited 2021 May 14];10(2):265.
- 461 Available from: /pmc/articles/PMC7828347/
- 462 26. Stovitz SD. In suspected SARS-CoV-2, rapid antigen detection tests had 67% to 73%
- 463 sensitivity and 98% to 100% specificity. Ann Intern Med [Internet]. 2021 May 4 [cited
- 464 2021 May 14]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/33939481
- 465 27. Crozier A, Rajan S, Buchan I, McKee M. Put to the test: Use of rapid testing technologies
- 466 for Covid-19. BMJ [Internet]. 2021 Feb 3 [cited 2021 May 14];372. Available from:
- 467 http://dx.doi.org/10.1136/bmj.n208

Table 1: Description of the study population

Descriptors		El Salvador	Paraguay	Wisconsin	New Jersey	N/Total (%)
		N/Total (%)	N/Total (%)	N/Total (%)	Atila	Optigene
Type of PCR	Abbott [®] RealTime	900/900	0	0	0	
(reference) test	SARS-COV-2 assay	(100.0%)				
	(Abbott, USA)					
	targeting RdRp and					
	N-genes					
	Cobas [®] SARS-COV-2	0	0	128/128	0	
	assay (Roche			(100.0%)		
	Diagnostics, USA)					
	targeting ORF-1a/b					
	and E-genes					
	STAT-NAT [®] COVID-19	0	265/265	0	0	
	MULTI assay (Sentinel		(100.0%)			

Diagnostics, Italy)				
targeting RdRP and				
ORF1b-genes				
Xpert Xpress SARS-	0	0	0	14/85# (16.5%)
COV-2 assay				
(Cepheid [®] , USA)				
targeting N2 and E-				
genes				
Simplexa [™] COVID-19	0	0	0	50/85# (58.8%)
Direct assay (DiaSorin				
Molecular, USA)				
targeting ORF-1ab				
and S-genes				

	Quest Diagnostics	0	0	0	1/85# (1.2%)
	lab-developed test				
	(LDT)				
PCR (reference)	Positive	163/900 (18.1%)	87/264 (33.0%)	18/126^	55/85 (64.7%)
result				(14.1%)	
PCR (reference)	<=20	57/163 (35.0%)	54/87 (62.1%)	N/A	10/55# (18.2%)
result by ct-values	21-25	17/163 (10.4%)	20/87 (23.0%)	-	20/55# (36.4%)
	26-30	24/163 (14.7%)	9/87 (10.3%)		7/55# (12.7%)
	31-35	26/163 (16.0%)	4/87 (4.6%)		14/55# (25.5%)
	>=36	39/163 (23.9%)	0		2/55# (3.6%)
Duration between	Parallal (Same day)	900/900	265/265	128/128	8/85 (9.4%)
sample collection		(100.0%)	(100.0%)	(100.0%)	
for PCR (reference)					
and test assay					

Duration be	tween	Same day	900/900		0		N/A		81/8	5	80/85	
sample colle	ection		(100.0%)						(95.3	%)	(94.1%	5)
for test assa	y and											
running the	assay											
Sample colle	ection	Nasopharyngeal	900	900	265	258	128	123	79	78	0	0
sites												
Total	Total	Saliva ^{***}	900	900	265	259**	128	126*	0	0	84	68*
sample	sample	Anterior Nares***	0	0	0	0	128	126	85	84	85	85
collected	with	Mid-turbinate***	0	0	0	0	127	122	0	0	0	0
	valid	Oropharyngeal	0	0	0	0	0	0	13	11	71	71
	result											
Age (years)		18-28	204/900 (22.	.7%)	118/265		N/A		N/A	1		
					(44.5%)							
		29-39	242/900 (26.	.9%)	74/265 (2	27.9%)						
		40-50	222/900 (24	.7%)	41/265 (15.5%)						

	>=51	232/900 (25.8%)	32/265 (12.1%)		
Gender	Male	425/900 (47.2%)	106/265	N/A	N/A
			(40.0%)		
	Female	475/900 (52.8%)	159/265		
			(60.0%)		
Symptomatic	Yes	272/900 (30.2%)	207/265	N/A	31/61 (50.8%)
			(78.1%)		
Total		900/1378	265/1378	128/1378	85/1378 (6.2%)
		(65.3%)	(19.2%)	(9.3%)	

470 N/A-Data not available; *All invalid runs were due to insufficient sample/mainly phlegm to process; **Three samples out of six total invalid runs were due to

471 insufficient sample/mainly phlegm to process; *** saliva, mid-turbinate, and anterior nares (at Wiconsin) were self-collected, # Type of RT-PCR data not

⁴⁷² available for 20 of 85 samples, Ct-values not available for 2 of 55 samples; ^RT-PCR results missing for 2 of 128 subjects.

474 Figure 1: Study site specific analysis of validity of Atila iAMP assay against PCR (Reference) test (not stratified by sample collection

475 site)



477 *P-value < 0.05 for McNemar's test (continuity corrected); **Any sample collection site positive out of the total samples collected is considered positive

Figure 2: Study site specific analysis of validity of Atila iAMP assay against PCR (Reference) test (stratified by sample collection 479



480 site)

482

483 *P-value < 0.05 for McNemar's test (continuity corrected); #Samples were tested in duplicates and the test was considered positive only if both were positive;

@Samples were tested in duplicates and the test was considered positive if either was positive 484

Figure 3: Study site and sample site specific analysis of the sensitivity of Atila iAMP assay against PCR (Reference) test stratified by



486 the ct-values



488 *Sensitivity for ct<35 and ct<30 was equal

490 Figure 4: Study site and sample site specific analysis of validity of Atila iAMP assay against PCR (Reference) test stratified by the





492

493 *P-value < 0.05 for McNemar's test (continuity corrected)

495 Figure 5: Study site specific analysis of validity of OptiGene Direct Plus RT-LAMP assay against PCR (Reference) test (overall and



496 stratified by sample collection site)

497

498 *P-value < 0.05 for McNemar's test (continuity corrected); **Any sample collection site positive out of the total samples collected is considered positive;

499 #Samples were tested in duplicates and the test was considered positive only if both were positive; @Samples were tested in duplicates and the test was



502 Acknowledgements

503

504	The field effort was a collaboration of the US National Cancer Institute	(NCI) with Basic Health
-----	--	------	---------------------

- 505 International (BHI), USA and Rutgers New Jersey Medical School (NJMS), USA. The BHI had
- 506 collaboration with Hospital Nacional de Santa Ana, El Salvador, Hospital Materno Infantil de San
- 507 Lorenzo, Ministerio de Salud Pública y Binestar Social (MSP-BS), Paraguay, Centro de
- 508 Especialidades Dermatológicas, MSP-BS, Paraguay, Instituto de Investigaciones en Ciencias de la
- 509 Salud, Universidad Nacional de Asunción, Paraguay, , and Medical College of Wisconsin, USA.
- 510
- 511 Funding
- 512
- 513 The research was funded by the intramural NCI Cancer MoonshotSM and intramural research
- 514 program.
- 515
- 516 **Conflict of Interest**

517

- 518 The authors have nothing to declare. None of the companies had any role in design, analysis,
- 519 interpretation, and finalization of the manuscript.

520

521 Author's contributions

523	NW, APN, NCD, JF, MM, RM, MC, KTD contributed substantially to the conception and design of
524	the study. KA, LM, MM, RD, AV, CDA, MM, JF, MP, APN, MHE contributed to acquisition of data.
525	MF, SG, NCD, BM contributed to running the test assays. KTD, LM, NW contributed to the
526	analysis and interpretation. KTD, NW drafted the manuscript. All authors provided critical
527	revision of the article and provided final approval of the version to publish.
528	
529	Ethical approval and informed consent
530	
531	The study was approved by the ethical review board of Comite Nacional de Etica de
532	Investigacion en Salud (IRB no.FWA00010986) in El Salvador, Comité de Ética, Instituto de
533	Investigaciones en Ciencias de la Salud, Universida Nacional de Asución (IRB no. P37/2020) in
534	Paraguay, MCW IRB (IRB no. FWA00000820) in Wisconsin, and the Newark Health Sciences IRB
535	for Rutgers Biomedical Health Sciences (IRB no. Pro2020001801) in New Jersey. Written
536	informed consent was obtained from all study participants.
537	
538	Availability of data
539	
540	The datasets used in the current study are available from the corresponding author on
541	reasonable request
542	
543	Abbreviations:
544	

545	CI	Confidence Interval
546	COVID-19	Coronavirus Disease of 2019
547	СТ	Cycle Threshold
548	EUA	Emergency Use Authorization
549	iAMP	Isothermal Amplification
550	IFU	Instruction for Use
551	LAMP	Loop-mediated Isothermal Amplification
552	LMIC	Low- and Middle- Income Countries
553	LOD	Limit of Detection
554	MCW	Medical College of Wisconsin
555	NAAT	Nucleic Acid Amplification Test
556	NP	Nasopharyngeal
557	ОР	Oropharyngeal
558	NJMS	Rutgers New Jersey Medical School
559	RT-PCR	Reverse Transcription-Polymerase Chain Reaction
560	SARS-COV-2	Severe Acute Respiratory Syndrome Coronavirus 2
561	SPSS	Statistical Package of Social Studies
562	VTM	Viral Transport Medium
563		